Laure V.
- Country
- France
- Department
- Clinical Hematology
Research Overview
- Phase 1b Evaluation of Bispecific T Cell Redirection Antibodies with Checkpoint Inhibitors in Relapsed/Refractory Multiple Myeloma Patients
- Efficacy and Safety of Etentamig and Daratumumab Versus Daratumumab and Combination Therapy in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase 2 Study of Mezigdomide, Carfilzomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Data & Insights
Has run more than one trial at 201 of 345 partner sites.
Specializations
Multiple Myeloma Research
The investigator specializes in conducting clinical research focused on multiple myeloma, with particular emphasis on both newly diagnosed and relapsed/refractory cases. Their work encompasses innovative therapeutic approaches including bispecific antibodies and monoclonal antibody treatments.
- Newly Diagnosed Multiple Myeloma Treatment
- Relapsed/Refractory Multiple Myeloma Management
- High-Risk Smoldering Multiple Myeloma
Novel Therapeutic Combinations
The researcher investigates various therapeutic combinations incorporating targeted therapies such as teclistamab, elranatamab, and daratumumab. Their work includes evaluation of novel drug combinations with immunomodulatory agents and proteasome inhibitors.
- Targeted Therapy Development
- Combination Treatment Strategies
- Maintenance Therapy Optimization
Special Population Studies
The investigator conducts research addressing specific patient populations, including studies focused on elderly patients and those with AL amyloidosis. Their work includes evaluation of treatment approaches for transplant-ineligible patients.
- Elderly Patient Care
- Transplant-Ineligible Patients
- AL Amyloidosis Treatment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.